Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 4
1(33.3%)
3Total
N/A(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06249763Not ApplicableCompleted

Effects of Gluten Free Diet in Ulcerative Colitis

Role: collaborator

NCT05350644Terminated

Inflammatory Bowel Disease(IBD), Treatment Response

Role: collaborator

NCT05414578Recruiting

NORDTREAT Prospective Study on Inflammatory Bowel Disease

Role: collaborator

NCT03173144Completed

Chronic Inflammatory Disease, Lifestyle and Treatment Response

Role: collaborator

NCT03586622Not ApplicableUnknown

One Year Home Monitoring and Treatment of IBS Patients

Role: collaborator

NCT00851565Phase 4Unknown

Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy

Role: collaborator

All 6 trials loaded